Forteo is Eli Lilly’s brand name for teriparatide, a daily self-injected pen that builds bone rather than just preserving it. You pick it up at a pharmacy and inject it yourself, so there is no clinic administration fee attached the way there is with the infused and clinic-injected osteoporosis drugs.

Forteo is also the one drug in this category where a cash payer has real leverage, because teriparatide now has multiple generic competitors and the price gap between brand and generic is enormous. Everything below was researched on September 3, 2026, and the generic figures have moved sharply within 2026, so vintage matters here more than usual.

What Does Forteo Cost Without Insurance?

Start with the pen. The FDA label describes a single-patient-use prefilled pen holding 560 mcg in 2.24 mL, intended to deliver 28 daily doses of 20 mcg, and instructs you to discard the device 28 days after first use. Every price below is per pen, which is a 28-day supply.

For the brand, two independent sources agree closely. CMS’s National Average Drug Acquisition Cost survey, which measures what retail pharmacies actually pay, priced Forteo at $1,841.00 per milliliter effective August 19, 2026. Multiplied by the 2.24 mL pen, that is $4,123.84. Drugs.com lists a cash price of $4,589.55 for the same pen. The gap between those two is roughly the pharmacy’s markup.

For the generic, the sources disagree wildly, and that disagreement is the story. NADAC puts the average pharmacy’s acquisition cost for a generic teriparatide pen at $494.81 per mL, or $1,108.36 per pen. Cost Plus Drugs sells one for $912.00. Drugs.com lists retail cash prices from $2,425.48 to $3,331.42. Same molecule, same device, a threefold spread depending on where you walk in.

Teriparatide pen (560 mcg / 2.24 mL, 28-day supply)LowTypicalHigh
Brand Forteo, cash$4,123.84$4,356.70$4,589.55
Generic teriparatide, cash$912.00$2,425.48$3,331.42
Generic, average pharmacy acquisition cost (CMS NADAC, Aug 19 2026)$1,108.36$1,108.36$1,108.36
Brand, one year at 13 fills$53,609.92$56,637.10$59,664.15
Generic, one year at 13 fills$11,856.00$31,531.24$43,308.46
Medicare Part D avg spending per Forteo claim, 2024$3,937.04$3,937.04$3,937.04
Medicare Part D avg spending per generic teriparatide claim, 2024$2,621.94$2,621.94$2,621.94
Lilly Cares Foundation, if you qualify$0$0$0

CMS’s 2024 Part D data confirms the brand-to-generic gap is real at scale. Brand Forteo averaged $1,571.07 per dosage unit ($3,519.19 per 2.24 mL pen) while generic teriparatide averaged $962.44 per dosage unit ($2,155.86 per pen), across $266.4 million and $212.6 million of spending respectively.

What Drives the Price

Brand versus generic is the whole ballgame. At the Cost Plus Drugs price of $912.00, a generic pen is 80% cheaper than the $4,589.55 Drugs.com brand cash price. Over a 13-fill year that is a difference of about $47,800. No other decision on this drug comes close.

Generic competition is still driving prices down. NADAC’s generic teriparatide vintages tell a clean story across 2026: $674.44 per mL in January, $624.89 in February, $595.54 in March, $540.38 in April, $535.09 in May, $536.55 in June, $520.91 in July and $494.81 effective August 19. Per pen that is a fall from $1,510.75 to $1,108.36, about 27% in seven months. CMS’s 2024 Part D data showed the same trend earlier, with per-unit spending down 22.9% for Teva, 29.8% for Prasco and 31.6% for Apotex year over year.

Where you fill it matters more than what you fill. A generic pen at retail can cost more than three times what the same pen costs at a direct-to-consumer pharmacy. NADAC says the average pharmacy pays $1,108.36 for it. If you are quoted $3,331, you are being asked for triple the pharmacy’s cost, and that is a number worth walking away from.

The 28-day pen does not line up with calendar months. Thirteen fills covers a year, not twelve. Any monthly budget built on twelve fills understates the annual cost by about 8%, and any savings program capped at twelve fills a year leaves one fill uncovered.

Refrigeration and waste. The Forteo label says to store the pen refrigerated at all times except when injecting, to minimize time out of the fridge, never to use it if frozen, and to throw the device away 28 days after first use. A pen ruined by a power outage or a bad shipping cold pack is a four-figure loss on brand and a three-figure one on generic.

Course length is capped, sort of. The label says use beyond two years in a lifetime should only be considered if a patient remains at or has returned to high fracture risk. Plan on two years of pens as the base case, then a cheaper maintenance drug to hold the gains.

Cash Price vs. Insurance

The Forteo savings card is the most visible number Lilly publishes and the least useful one for an uninsured reader. Its terms state you can pay as little as $4 for a one-month (28-day) fill, with maximum annual savings of $10,600 and up to 13 fills per calendar year, and the card expires December 31, 2026. To use it you must be enrolled in a commercial drug insurance plan with coverage for Forteo, be a U.S. or Puerto Rico resident, be 18 or older, and not be in Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA or TRICARE. Uninsured patients are excluded by design.

The generic makers run the same structure. Drugs.com records a Prasco teriparatide copay card offering as little as $0 with up to $250 off per fill, and a Teva teriparatide savings card offering as little as $0 through December 31, 2026. Both require commercial insurance. None of these programs is available to a cash payer.

What is available to a cash payer is the Lilly Cares Foundation. Forteo is a Group 1 medication there, which covers patients who have no insurance or Medicare Part D and whose household adjusted gross income is at or below 300% of the 2026 federal poverty guidelines. For 2026 that is $47,880 for one person, $64,920 for two, $81,960 for three and $99,000 for four. Applicants must also not be in Medicaid, full Low-Income Subsidy or VA benefits. Alaska and Hawaii limits differ.

If you do have Medicare Part D, note that the annual out-of-pocket cap now applies, and a year of teriparatide will almost certainly reach it. CMS’s 2024 data showing $23,296.84 in average Part D spending per Forteo beneficiary is the plan’s share, not what a patient paid.

How to Pay Less

  1. Ask for the generic by name. Teriparatide injection, 560 mcg / 2.24 mL. There are multiple approved products from Teva, Apotex, Amphastar, Almaject and Alvogen (marketed as Bonsity), plus a Prasco authorized generic. Handing your prescriber the words “generic teriparatide” is the difference between an $11,856 year and a $59,664 one.

  2. Price a direct-to-consumer pharmacy against your local one. Cost Plus Drugs lists teriparatide at $912.00 per pen, below what CMS says the average retail pharmacy pays to acquire it. Get a written cash quote from your regular pharmacy too, then compare. Our guide to GoodRx vs. SingleCare covers how discount cards behave on high-cost pens, and our fair price checker helps you judge a quote you have been given.

  3. Apply to Lilly Cares if you are staying on the brand. Forteo is Group 1, income at or below 300% of the 2026 federal poverty guidelines, no insurance or Medicare Part D. Apply before you pay for a pen, not after.

  4. Use the NADAC number as your negotiating anchor. A pharmacy that pays $1,108.36 for a generic pen and quotes you $3,331 is charging a 200% markup. Say the acquisition cost out loud and ask for their cash price rather than their list price. The same posture works on medical bills generally, which our guide to negotiating medical bills walks through.

  5. Time your fills so you never waste a pen. Twenty-eight days from first injection, then discard. Do not start a pen right before a trip, and do not accept a two-pen shipment unless you have fridge space and a plan for the second one.

  6. Budget for the surrounding care, not just the drug. Two years of therapy means bone density monitoring and follow-up visits. A DEXA scan has its own cash price, a free or sliding-scale clinic can handle routine follow-up, and if a hospital system bills you for any of it, hospital charity care may wipe out the balance.

Bottom Line

Brand Forteo runs about $4,124 to $4,590 per 28-day pen as of September 2026, or roughly $54,000 to $60,000 for a 13-fill year. Generic teriparatide is the same molecule in the same device, and it starts at $912.00 a pen at Cost Plus Drugs, which is about $11,900 a year. That is the single largest brand-to-generic spread on any drug in the bone health category, and it is still widening as CMS acquisition costs fall.

If your prescriber wants an anabolic drug and cost is the constraint, generic teriparatide is the cheap end of that shelf. Tymlos is the other daily self-injected option and has no generic, so it runs about $2,640 to $2,935 a month. Evenity is anabolic but clinic-administered, which adds an administration bill. Afterward, the bone-preserving drugs that hold the gains cost far less: see Prolia, Reclast and alendronate, which CMS prices at about 26 cents per 70 mg weekly tablet. If postmenopausal bone loss is the underlying issue, hormone therapy is a separate and much cheaper conversation.